Literature DB >> 25800548

Changes in Drug Utilization and Outcome With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy.

Justin Penn1, Ilan Goldenberg2, Scott McNitt3, Bronislava Polonsky3, Martin H Ruwald3, Wojciech Zareba3, Arthur J Moss3, Jeffrey D Alexis4.   

Abstract

BACKGROUND: This study sought to assess the association between medication utilization, outcome, and the efficacy of resynchronization therapy in the MADIT-CRT study. METHODS AND
RESULTS: Medication use by patients in the MADIT-CRT study was analyzed. Time-dependent Cox proportional hazard regression analyses were performed to assess differences in hospitalization for heart failure (HF) or death. The greater the efficacy of cardiac resynchronization therapy (CRT) as measured by reduction in left ventricular end-systolic volume (LVESV) and increase in left ventricular ejection fraction (LVEF) between baseline and 1 year of follow-up, the greater the likelihood that patients remained on an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) and avoided use of or reduced treatment with diuretics. Treatment with diuretics was associated with a significantly increased risk of HF hospitalization or death (hazard ratio [HR] 1.87, 95% confidence interval [CI] 1.45-2.41; P < .001). In contrast, treatment with an ACE-I/ARB was associated with a significantly decreased risk of HF hospitalization or death (HR 0.58, 95% CI 0.42-0.80; P = .001).
CONCLUSIONS: In HF patients in New York Heart Association functional classes I and II and with wide QRS complexes, efficacy of CRT as measured by improvement in LVESV and LVEF was associated with an increased likelihood of remaining on an ACE-I/ARB and discontinuing diuretic therapy. Discontinuation of diuretics was reflective of improved hemodynamic response to CRT.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure; angiotensin receptor blocker; angiotensin-converting enzyme inhibitor; diuretic; resynchronization

Mesh:

Substances:

Year:  2015        PMID: 25800548     DOI: 10.1016/j.cardfail.2015.03.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  5 in total

Review 1.  Non-response to Cardiac Resynchronization Therapy.

Authors:  Syed Yaseen Naqvi; Anas Jawaid; Ilan Goldenberg; Valentina Kutyifa
Journal:  Curr Heart Fail Rep       Date:  2018-10

Review 2.  Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?

Authors:  Brian Kerr; Rebabonye B Pharithi; Matthew Barrett; Carmel Halley; Joe Gallagher; Mark Ledwidge; Kenneth McDonald
Journal:  Int J Heart Fail       Date:  2021-02-25

3.  Cardiac resynchronization therapy outcomes in patients under nonoptimal medical therapy.

Authors:  Belén Alvarez-Alvarez; Javier García-Seara; Jose L Martínez-Sande; Moisés Rodríguez-Mañero; Xesús A Fernández López; Laila González-Melchor; Rosa M Agra Bermejo; Diego Iglesias-Alvarez; Francisco Gude Sampedro; Carla Díaz-Louzao; José R González-Juanatey
Journal:  J Arrhythm       Date:  2018-08-07

4.  Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement.

Authors:  Samaneh Salimian; Marc W Deyell; Jason G Andrade; Santabhanu Chakrabarti; Matthew T Bennett; Andrew D Krahn; Nathaniel M Hawkins
Journal:  Heart Rhythm O2       Date:  2021-12-17

5.  Impact of diabetes on clinical outcome of patients with heart failure undergoing ICD and CRT procedures: results from the German Device Registry.

Authors:  Elif Kaya; Jochen Senges; Matthias Hochadel; Lars Eckardt; Dietrich Andresen; Hüseyin Ince; Stefan G Spitzer; Thomas Kleemann; Sebastian S K Maier; Werner Jung; Christoph Stellbrink; Tienush Rassaf; Reza Wakili
Journal:  ESC Heart Fail       Date:  2020-02-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.